Shots:

• BMS to receive $65M up front- including $15M equity investment and is eligible to receive $3B as license fees- discovery- development- regulatory and commercial milestones- in addition to royalty payments on commercialization of each product commercialized by BMS
• The companies will Repare’s SNIPRx platform to jointly identify multiple synthetic lethal precision oncology targets for drug candidates. BMS will get exclusive WW rights to develop and commercialize therapies for select validated synthetic lethal precision oncology targets emerges during the collaboration
• Repare’s SNIPRx platform is a genome-wide CRISPR-based screening platform that utilizes isogenic cell lines to identify synthetic lethal gene pairs and the corresponding patients who may get benefit from therapies

Click here to read full press release/ article |

Ref: Business wire | Image: BMS